Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer

Open access
Kulke, Matthew H., Blaszkowsky, Lawrence S., Ryan, David P., Clark, Jeffrey W., Meyerhardt, Jeffrey A., Zhu, Andrew X., Enzinger, Peter C., Kwak, Eunice L., Muzikansky, Alona, Lawrence, Colleen, Fuchs, Charles S.·2007·Journal of Clinical Oncology

Abstract

Purpose: The addition of either capecitabine or erlotinib to gemcitabine in the first-line treatment of advanced pancreatic cancer is associated with modest improvements in overall survival. We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine. Patients and Methods: Thirty patients with gemcitabine-refractory metastatic pancreatic cancer were treated with capecitabine, administered at a dose of 1,000 mg/m 2 twice daily for 2 weeks, followed by a 1-week break. All patients also received erlotinib 150 mg daily. Patients were observed for evidence of response, toxicity, and survival. EGFR mutational status was assessed in available tumor blocks. Results: Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and a median survival duration of 6.5 months. In addition, 17% of the treated patients experienced decreases in tumor marker (CA 19-9) levels of more than 50% from baseline. Common toxicities included diarrhea, skin rash, fatigue, and hand-foot syndrome. EGFR mutations were detected in two of five available tumors; no association between treatment response and EGFR mutational status was evident. Conclusion: The combination of capecitabine and erlotinib is active in patients with gemcitabine-refractory pancreatic cancer. This regimen may represent an acceptable treatment option in patients who experience treatment failure with standard first-line therapy with gemcitabine or for whom gemcitabine may not be an appropriate first-line treatment option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.11.8521

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Kulke, M. H., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Kwak, E. L., Muzikansky, A., Lawrence, C., & Fuchs, C. S.
Venue
Journal of Clinical Oncology
Published
2007-10-20
Volume
25
Issue
30
Pages
4787-4792
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1989245824
Cited by
166
References
2
FWCI
9.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer. https://app.cochat.ai/papers/10.1200/jco.2007.11.8521
The paper
Kulke, M. H., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Kwak, E. L., Muzikansky, A., Lawrence, C., & Fuchs, C. S. (2007). Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.11.8521

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.